Revolution Medicines' daraxonrasib nearly doubles pancreatic cancer survival in late-stage trial
Updated
Updated · The Wall Street Journal · Apr 28
Revolution Medicines' daraxonrasib nearly doubles pancreatic cancer survival in late-stage trial
10 articles · Updated · The Wall Street Journal · Apr 28
The pill, which targets RAS mutations, could receive FDA approval later this year and may generate billions in annual sales.
Recent talks with Merck and AbbVie valued Revolution Medicines at around $30 billion, but no acquisition occurred; its market cap now nears $40 billion, making a buyout unlikely.
With a strong pipeline in other cancers and limited appetite for megadeals among Big Pharma, Revolution Medicines may follow the path of independent biotech giants like Vertex and Regeneron.
Is Revolution Medicines' $40 billion price tag a bubble or the future of biotech?
Could this drug's success break the Big Pharma acquisition model for good?
Beyond cancer, what other 'undruggable' diseases could this new technology conquer?
What major hurdles could still derail this promising pancreatic cancer breakthrough?
This new pill doubles survival, but what will it cost patients and healthcare systems?
How will cancer evolve to resist this revolutionary new 'molecular glue' drug?